PF-06372865   Click here for help

GtoPdb Ligand ID: 9798

Synonyms: darigabat (proposed INN) | example 4 [WO2014091368] | PF06372865
Compound class: Synthetic organic
Comment: PF-06372865 is an orally active, GABAA receptor positive allosteric modulator, that selectively targets GABAA receptors containing α2/3/5 subunits over receptors containing α1 subunits [1,3]. The α1 subunit is associated with the (undesirable) sedative effects of benzodiazepine drugs, whilst the α2/3 subunits contribute to their anxiolytic and analgesic activities and the α5 subunit to effects on memory function. The chemical structure of PF-06372865 is claimed as 'Example 4' in patent WO2014091368 [2]. Pfizer are developing PF-06372865 for clinical potential in the treatment of chronic pain [4] and photosensitive epilepsy, but have terminated development in generalized anxiety disorder.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 95.35
Molecular weight 440.13
XLogP 4.53
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc(ccc1c1cc(ccc1F)c1cnnc2c1ncn2CC)S(=O)(=O)CC
Isomeric SMILES COc1cc(ccc1c1cc(ccc1F)c1cnnc2c1ncn2CC)S(=O)(=O)CC
InChI InChI=1S/C22H21FN4O3S/c1-4-27-13-24-21-18(12-25-26-22(21)27)14-6-9-19(23)17(10-14)16-8-7-15(11-20(16)30-3)31(28,29)5-2/h6-13H,4-5H2,1-3H3
No information available.
Summary of Clinical Use Click here for help
PF-06372865 has completed a Phase 2 clinical trial in patients with photosensitive epilepsy (NCT02564029). In this trial PF-06372865 was compared with lorazepam (as a positive control) and placebo. A Phase 2 study in patients with chronic low back pain has also been completed (NCT02262754). Click here to link to's full list of PF-06372865 trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02262754 PF-06372865 In Subjects With Chronic Low Back Pain Phase 2 Interventional Pfizer
NCT02564029 PF-06372865 in Subjects With Photosensitive Epilepsy Phase 2 Interventional Pfizer